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Abstract
Attenuation of increased endocannabinoid signaling with a CB1R neutral antagonist might offer a
new therapeutic direction for treatment of alcohol abuse. We have recently reported that a mono-
hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits
neutral antagonist activity at CB1Rs and thus may serve as a promising lead for the development
of novel alcohol abuse therapies. In the current study, we show that systematic modification of an
aminoalkylindole scaffold identified two new compounds with dual CB1R antagonist/CB2R
agonist activity. Similar to the CB1R antagonist/inverse agonist rimonabant, analogues 27 and 30
decrease oral alcohol self-administration, without affecting total fluid intake and block the
development of alcohol-conditioned place preference. Collectively, these initial findings suggest
that design and systematic modification of aminoalkylindoles such as 3 may lead to development
of novel cannabinoid ligands with dual CB1R antagonist/CB2R agonist activity with potential for
use as treatments of alcohol abuse.
Introduction
The abuse of drugs and alcohol is often associated with substantial psychiatric comorbidity
and exacerbates the spread of HIV/AIDS and drug resistant tuberculosis.1 Estimates of the
total overall cost of substance abuse in the United States, including productivity, health- and
crime-related costs, exceeds $600 billion annually.2 This includes approximately $193
billion for use of illicit drugs, $193 billion for tobacco, and $235 billion for alcohol.3–5
The World Health Organization estimates that approximately 2.5 million people die from
alcohol use every year.6 While several therapeutic options are available for the treatment of
alcohol abuse, all existing therapies have only modest efficacy.7 A growing body of
evidence suggests that the endocannabinoid system is involved in some of the abuse related
effects of drug and alcohol dependence.8 For example, studies have shown that chronic
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ethanol (EtOH) exposure down-regulates cannabinoid 1 receptors (CB1Rs) and increases the
brain concentration of endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol
(2-AG).9, 10 It has also been demonstrated that CB1R knock-out mice exhibit reduced
voluntary alcohol consumption as compared to wild type mice.11 Furthermore, the CB1R
antagonist/inverse agonist rimonabant (SR141716A, Figure 1) reduces EtOH intake in
C57B1/6J mice to levels comparable with that of CB1−/− mice.12 Cannabinoid 2 receptors
(CB2Rs) have also been implicated in substance abuse. Systematic administration of the
CB2R agonist 1 (JWH-133) dose-dependently inhibits intravenous cocaine self-
administration in wild-type and CB1R-deficient mice, but not in CB2R-deficient mice and
this effect was blocked by the CB2R antagonist 2 (AM630).13, 14 To determine if this effect
was mediated by antagonism of central or peripheral CB2Rs, the authors microinjected 2
into the nucleus accumbens and again observed antagonism of the reduction in cocaine self-
administration induced by systemic administration of the CB2R agonist 1.13 Collectively,
these studies suggest that targeting the central cannabinoid signaling system has potential in
treating drug and alcohol dependence.
One approach to developing cannabinoid-based drugs for treatment of alcohol abuse is to
target a molecule that possesses both CB1R neutral antagonist and CB2R agonist activity.
This combined pharmacological profile offers two advantages over presently available
CB1R antagonists/inverse agonists. Firstly, it provides an opportunity to avoid the side
effect profile seen with rimonabant. During the first year of a RIO-Europe clinical trial
several moderate side effects of rimonabant treatment were observed, including nausea,
dizziness, and diarrhea.15 However, upon completion of a meta-analysis study in 2007, it
was concluded that a therapeutic dose of rimonabant produced very serious psychiatric side
effects such as depression, anxiety and suicide.16, 17 However, subsequent studies in animals
indicate that a neutral antagonist might be expected to retain the therapeutic properties of
rimonabant, but be associated with fewer adverse effects resulting from inverse agonism at
CB1Rs.18–20 Secondly, incorporation of CB2 agonism into the same molecule provides an
opportunity to harness a potential new direction in developing anti-addiction therapies. Our
approach to identifying such a molecule has been to investigate synthetic cannabinoids.
Synthetic cannabinoids derived from the aminoalkylindole structural class have received
increased attention due to recent widespread abuse of the incense blends known as K2/
Spice.21 Despite the recreational popularity of these commercial preparations, very little is
known regarding K2/Spice metabolism, pharmacology, and toxicity. Among the most
common components of K2/Spice are naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone
(JWH-018), (1-butyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (JWH-073), (1-(2-
morpholinoethyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone (JWH-200), and 2-((1S,3R)-3-
hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol (CP-47,497, Figure 2).22 These agents
exhibit differential selectivity towards CB1Rs and CB2Rs and have been shown to be both
more potent than the classical cannabinoid Δ9-THC.23, 24 Recently, our group reported that a
mono-hydroxylated metabolite of aminoalkylidole 3 (JWH-073), compound 4 (JWH-073-
M4), retains relatively high affinity for CB1Rs, but lacks intrinsic activity when examined in
the [35S]GTPγS functional assay.25 These results indicate that this metabolite may act as a
neutral antagonist at CB1Rs.
Given our results that 4 acts as a neutral antagonist at CB1Rs and the known promiscuity of
the aminolakylindoles for both CB1 and CB2 receptors, we hypothesize that further
structure-activity relationships (SAR) would identify analogues with dual CB1R neutral
antagonist/CB2R agonist activity.23, 24, 26 Results from our initial results are described
below.
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Synthesis of analogues based on scaffold 4 began with the use of commercially available 7-
methoxyindole (5), which was subjected to mild alkylating conditions to afford compound
(6), an important intermediate in 74–93% yield for the different substituents, respectively
(Scheme 1). In addition, commercially available 7-ethylindole was also subjected to the
aforementioned conditions to yield compound (6) with an ethyl substitution at the 7-position
of the indole ring in 93% yield. Intermediate 6 was then subjected to Friedel-Crafts like
acylation conditions, using dimethyaluminum chloride and the appropriate acid chloride at 0
°C to afford many of the analogues prepared, structurally represented as intermediate (7), in
yields ranging from 9–68%. Compound 7 was shown to be a versatile intermediate that can
undergo several reactions to yield various scaffolds. Specifically, it undergoes O-
demethylation in the presence of BBr3 to afford compound (8) in yields ranging from 38%–
90% as well as LAH reduction conditions to afford compound (9) in 20% yield. 1-butyl-5-
methoxy-1H-indole, 11 synthesized from N-alkylation of commercially available 5-
methoxyindole 10, was subjected to Friedel-Crafts like acylation conditions to produce
compound (12) in 58% yield, which was then O-demethylated using BBr3 to afford
compound (13) in 90% yield (Scheme 2). Compound 5 was additionally used in the
synthesis of intermediate (14) utilizing a one-pot N-alkylation and 3-indole iodination in
69% yield. Intermediate 14 was then subjected to Suzuki coupling conditions utilizing
different boronic acids to afford analogues (15) and (16) in 37% and 50% yield,
respectively. Twenty-one analogues were synthesized and the structures of the analogues are
schematically represented in Table 1.
Results and Discussion
In our quest for novel dual activity compounds with CB1R neutral antagonist/CB2R agonist
properties, twenty-one analogues were prepared using step-wise molecular investigation of
the elements present in the scaffold of compound 4. The analogues prepared were designed
to investigate the SAR at several positions on the scaffold of interest. Firstly, we wanted to
examine the necessity of the carbonyl moiety as well as the optimal length of the linker from
the indole core to the naphthalene ring. We also sought out to explore the possibility for
addition of rotational bonds at this position of the molecule. Secondly, we set to explore the
requirement of the naphthalene ring through selective introduction of electron withdrawing
and electron donating groups. Our initial design strategy was to limit the use of charged
species and keep steric demands to a minimum. Lastly, we wanted to investigate the
positioning of the hydroxyl moiety around the indole core and its necessity for activity at
CBRs. The prepared analogues were subjected to in vitro pharmacological characterization,
which included receptor binding and functional assays for both cannabinoid receptors. Initial
receptor binding screens for both CB1Rs and CB2Rs were conducted for all twenty-one
analogues prepared. These initial binding screens were conducted by examining the ability
of a single analogue concentration of 1 μM to compete for receptor binding with the high
affinity CB1/CB2R agonist [3H]CP-55,940.27, 28 This approach allowed us to quickly attain
an approximate affinity of all compounds tested at the cannabinoid receptors. Compounds
were selected for further assays to determine intrinsic activity at CB1 and CB2Rs if a 1 μM
concentration produced over 50% displacement of a 0.2 nM concentration of
[3H]CP-55,940, indicating a relatively high sub-micromolar affinity. For example,
employing the conditions used for this screen, it would be predicted by the Cheng-Prusoff
equation that the concentration of a compound producing 50% displacement of
[3H]CP-55,940 from a receptor will estimate the compounds affinity for that receptor.29
Data presented in Table 1 shows that a 1μM concentration of most analogues examined
produced greater than 50% displacement of [3H]CP-55,940 from both CB1R and CB2Rs. As
a result, out of the twenty-one analogues that were screened, sixteen bind to CB1R and
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eighteen bind to CB2R with sub-micromolar affinity. Several analogues exhibited very high
affinity for either of the two receptors tested, which can be predicted from their near 100%
displacement of [3H]CP-55,940 from the receptors. Based on the above criteria, thirteen
compounds were chosen for further evaluation.
A functional assay to screen for the inhibition of adenylyl cyclase (AC) activity by CBRs
was selected for determination of intrinsic activity of the analogues that demonstrated sub-
micromolar affinity for CB1R and CB2Rs.28 Since all analogues examined are predicted to
bind to CBRs with sub-micromolar affinity, a 10 μM concentration of all compounds was
used to achieve full-receptor occupancy. It is assumed that full-receptor occupancy will
produce maximal efficacy. The non-selective CB1R/CB2R full agonist CP-55,940 inhibited
AC-activity via CB1Rs endogenously expressed in Neuro2A cells by 45% and 37% in CHO
cells transfected with CB2 receptors (Table 1). Most compounds examined exhibited levels
of AC-inhibition similar to that produced by the full agonist CP-55,940. Unlike our prior
report demonstrating that metabolite 4 exhibited neutral antagonist properties in assays
examining G-protein activation, in this study 4 interestingly acts as a full CB1R agonist to
inhibit AC-inhibition in Neuro2A cells.25 However, compounds 17, 27, and 30, produced
significantly less AC-inhibition via CB1Rs when compared to the full agonist CP-55,940 of
−4, 18, and 16% inhibition, respectively. Despite little or no AC-inhibition when examined
at CB1Rs, these compounds exhibited significantly different results when tested for activity
at CB2Rs. Specifically, the three compounds 17, 27, and 30 produced levels of AC-
inhibition that were similar to inhibition resulting from CP-55,940 administration of 22.1,
33.2, and 20.8%, respectively. Collectively, these data indicate that compounds 17, 27, and
30 display only neutral antagonist to weak partial agonist activity at CB1Rs, while
exhibiting partial to full agonist efficacy at CB2Rs.
Based on efficacy predicted from functional experiments examining AC-inhibition, together
with the initial screen for sub-micromolar receptor affinity, several compounds were
selected to determine actual Ki values by conducting full concentration effect curves for
inhibition of [3H]CP-55,940 binding to CBRs. Even though compound 17 produced minimal
AC-inhibition via CB1Rs, it was shown to bind to both CB1 and CB2Rs with a relatively
low affinity of 387 and 281 nM, respectively (Table 2). However, analogue 19 demonstrated
high affinity for CB1 and CB2Rs in the low nanomolar range of 1.7 nM and 0.81 nM,
respectively. Compounds 27 and 30 displayed similar affinity for both receptors, however
binding with slightly higher affinity to the CB2R. Specifically, 27 bound to CB1Rs with a Ki
value of 15.4 nM, while binding to CB2Rs with a Ki value of 10.9 nM. Compound 30
demonstrated an affinity of 37.2 nM and 26.5 nM for CB1R and CB2Rs, respectively.
The four lead compounds exhibiting relatively high affinity as indicated by Ki values were
examined together with metabolite 4 to determine their potency to inhibit AC-activity via
CB1 and CB2Rs. Similar to data reported in the initial screen for AC-inhibition, 4 and 19
produced 50–60% inhibition of AC-activity via CB1Rs with IC50 values of 225 and 45 nM,
respectively. Conversely, 27 and 30 produced very little inhibition of AC-activity, which
was only observed at very high concentrations of both analogues (Figure 3A). In support of
the observed functional activity indicating neutral antagonism, the two lead compounds and
the CB1R antagonist O-2050 (1 μM concentration) significantly antagonized AC-inhibition
produced by the CB1R full agonist 3 (Figure 3B). In contrast to neutral antagonism at
CB1Rs, all of the compounds examined produced 40–50% inhibition of AC-activity at
CB2Rs in CHO-hCB2 cells with potency similar to their rank order of Ki values reported in
Table 2 (Figure 4A). To examine if the observed agonist activity in CHO-hCB2 cells is due
to activation of CB2Rs, the AC-inhibition assay was conducted in CHO-WT cells not
expressing CB2Rs. As observed in Figure 4B, neither 27 nor 30 significantly modified AC-
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activity in CHO-WT cells indicating that the agonist activity observed for both compounds
in CHO-hCB2 cells is indeed due to their activation of CB2Rs.
The dual CB1R neutral antagonist/CB2 agonist activity displayed by compounds 27 and 30
in the in vitro assays prompted us to select these analogues for further evaluation in vivo
using murine subjects in two complementary models relevant to alcohol abuse. Our
hypothesis is that an analogue with dual activity as CB1R neutral antagonist/CB2R agonist
will reduce both the reinforcing effects of EtOH and the conditioned rewarding effects of
EtOH in mice. The compounds selected were initially tested for potential cannabinoid
receptor antagonist activity using a thermoregulation assay. The hypothermic effects of
cannabinoid agonists are well established, and are blunted by prior treatment with CB1R
antagonists, allowing us to rapidly determine whether or not our selected compounds display
in vivo effects consistent with CB1R antagonism.30, 31 The assay was conducted using glass-
encapsulated radiotelemetry probes surgically implanted into the peritoneal cavity of each
mouse, which monitored core body temperature in response to drug administration.25
Intraperitoneal administration of 10 mg/kg of the full CB1R agonist 3, elicited a profound
hypothermic effect as seen in Figure 5 (black circles). Importantly, thirty minute
pretreatment with either 27 (Figure 5, gray triangle) or 30 (Figure 5, white circles),
significantly decreased the hypothermic effects elicited by subsequent administration of
compound 3, confirming the in vivo cannabinoid activity of 27 and 30, and illustrating
apparent antagonist effects against CB1R agonist-induced hypothermia.
Having established apparent in vivo antagonism, 27 and 30 were further tested in two
complementary models of alcohol abuse: oral self-administration (SA) and alcohol
conditioned place preference (CPP). These assays are important models for the study of
alcoholism because they capture several aspects of this condition including voluntary EtOH
drinking (SA) and conditioned EtOH reward (CPP). The effects of compounds 27 and 30 on
voluntary 10% EtOH drinking were studied using a two-bottle choice procedure (ethanol vs.
water) similar to those described by Keane and coworkers, as well as by Cunningham and
coworkers, using 10 mg/kg rimonabant as a positive control.32, 33 Across five observations
conducted under baseline “no injection” conditions it can be observed in Figures 6A, and 6D
(black circles) that EtOH preference and total fluid consumption (Figure 6B, Figure 6E;
black circles) were steadily maintained during the entire treatment period. Consistent with
previous reports, daily treatment with 10 mg/kg rimonabant decreased EtOH preference
(Figure 6A, Figure 6D, triangles) without altering total fluid intake (Figure 6B, Figure 6E,
triangles).34 However, consisted with previously published reports, rimonabant decreased
body weight across the treatment period (Figure 6C, Figure 6F, triangles).35, 36 After ten day
treatment with rimonabant, mice were returned to baseline “no injection” conditions where
their weights increased and voluntary EtOH drinking resumed. After five such observations,
representing a two week drug “washout” period, daily treatments with 10 mg/kg of 27 or 30
were initiated. As previously observed with rimonabant, both compounds 27 and 30 reduced
EtOH preference (Figure 6A, inverted triangles; Figure 6D, gray triangles, respectively)
without affecting total fluid consumption (Figure 6B, inverted triangles; Figure 6E, gray
triangles). However, unlike rimonabant, compounds 27 and 30 did not decrease body weight
of mice tested (Figure 6C, inverted triangles; Figure 6E, gray triangles). The last treatment
was a daily injection of the rimonabant/27/30 vehicle, which was 8% Tween/92% sterile
water. With the exception of the first observation period for compound 27 (perhaps
representing a persistent effect of 27), EtOH preference (Figure 6A, gray circles-compound
27; Figure 6D, gray circles-compound 30), total fluid consumption (Figure 6B, gray circles-
compound 27; Figure 6E, gray circles-compound 30), and mean body weight (Figure 6C,
gray circles-compound 27; Figure 6F, gray circles-compound 30) were not affected by
vehicle injections. This study demonstrates that a JWH-derived compound devoid of inverse
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agonist activity can replicate the effects of rimonabant on alcohol self-administration in
mice.
To further explore the in vivo effects of these compounds, an alcohol conditioned place
preference assay was performed with compounds 27, 30, and rimonabant. This assay tested
the effects of these compounds on the conditioned rewarding effects of EtOH. Training of
mice involved daily pairings of 2 mg/kg EtOH with novel contextual cues within a spatial
conditioning chamber, and daily pairings of saline with distinct contextual cues within the
same chamber. Following four such pairings, an increase in time spent in EtOH-paired
chamber was observed, indicating the development of conditioned place preference (Figure
7, “No inj” bar). Separate groups of mice were conditioned as previously described, with the
exception that 10 mg/kg 27, 10 mg/kg 30 or 10 mg/kg rimonabant were administered one
hour before each EtOH pairing. In contrast to the ~400 sec preference elicited by EtOH in
the absence of cannabinoid administration, mice treated with 10 mg/kg rimonabant prior to
each EtOH pairing did not exhibit a significant preference for the EtOH-paired chamber,
which is in agreement with previously reported data (Figure 7, “10 RIM” bar).37, 38 Similar
to the effects of rimonabant produced in the present study, the conditioned rewarding effects
of EtOH were also blocked by the administration of either 10 mg/kg 27 or 10 mg/kg 30 prior
to each EtOH pairing. In total, these studies demonstrate that a novel indole-derived
compound with cannabinoid activity lacking inverse agonist activity can replicate the effects
of rimonabant on alcohol induced CPP in mice.
Conclusions
CBR ligands that attenuate endocannabinoid signaling have been shown to produce effects
in several disorders, among which are drug abuse and alcohol dependence.16, 39 Our goal is
to design and synthesize a dual activity CB1R neutral antagonist/CB2R agonist that would
reduce increased endocannabinoid signaling without affecting intrinsic CB1R activity, and
also be able to modulate the rewarding effects of alcohol abuse. As an initial step towards
achieving this goal, we conducted experiments to synthesize compounds that exhibit dual
CB1R neutral antagonist/CB2R agonist activity based on the scaffold of compound 4. Initial
studies explored the scaffold of 4 by utilizing a molecular dissection approach to better
understand the elements involved in producing cannabinoid activity. The necessity of the
naphthalene ring and the electronic potential at this position, the necessity of the carbonyl
moiety, the length of the linker between the indole core and the naphthalene substituent, as
well as the necessity of the hydroxyl moiety on the 7-position of the indole ring were all
explored. Similar to the parent compound 3, the majority of the analogues examined
exhibited relatively high affinity for both CB1R and CB2Rs. Of all of the compounds tested,
two analogues, 27 and 30, appeared to have the most promise. For example, compounds 27
and 30 displayed similar high affinity for both receptors, with Ki values of 27 of 15.4 nM at
CB1R and 10.9 nM for CB2R and Ki values of 30 of 37.2 and 26.5 nM for CB1R and
CB2R, respectively. In AC-inhibition assays, both compounds produced very little inhibition
of AC-activity via CB1Rs, consistent with neutral antagonism. However, 27 and 30 both
produced 40–50% inhibition of AC-activity via CB2Rs, similar to that of the full agonist
CP-55,940 and thus consistent with partial to full agonism. Based on promising results from
these in vitro studies, compounds 27 and 30 were selected for testing in two in vivo models
of alcohol abuse: oral self-administration and alcohol conditioned place preference. Similar
to the actions produced by the CB1R antagonist/inverse agonist rimonabant, both 27 and 30
were shown to decrease alcohol self-administration, without affecting total fluid intake.
Unlike rimonabant, 27 and 30 did not alter body weight during the treatment period.
Interestingly, both 27 and 30 decreased alcohol conditioned place preference in a similar
manner to rimonabant, despite not possessing any apparent inverse agonist activity in vitro.
As has been previously reported for rimonabant, results from the present study collectively
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demonstrate that both the reinforcing and conditioning rewarding effects of alcohol can also
be significantly blunted by treatment with novel JWH-derived cannabinoids, devoid of
inverse agonist activity at CB1Rs.40 Such compounds with dual CB1R neutral antagonist/
CB2R agonist activity may indeed represent potential leads in an ongoing search for new
and improved alcohol abuse therapies. Additional data will be reported in due course.
Experimental section
General Methods
Unless otherwise indicated, all reagents were purchased from commercial sources and were
used without further purification. Melting points were determined on a Thomas-Hoover
capillary melting apparatus. NMR spectra were recorded on a Bruker DRX-400 with qnp
probe or a Bruker AV-500 with cryoprobe using δ values in ppm (TMS as internal standard)
and J (Hz) assignments of 1H resonance coupling. High resolution mass spectrometry data
were collected on either a LCT Premier (Waters Corp., Milford, MA) time of flight mass
spectrometer or an Agilent 6890 N gas chromatograph in conjunction with a quarto Micro
GC mass spectrometer (Micromass Ltd, Manchester UK). Thin-layer chromatography
(TLC) was performed on 0.25 mm plates Analtech GHLF silica gel plates using ethyl
acetate/n-hexanes, in 20%:80% ratio as the solvent unless otherwise noted. Spots on TLC
were visualized by UV (254 or 365 nm), if applicable, and phosphomolybdic acid in ethanol.
Column chromatography was performed with Silica Gel (40–63 μ particle size) from
Sorbent Technologies (Atlanta, GA). Analytical HPLC was carried out on an Agilent 1100
Series Capillary HPLC system with diode array detection at 254 nm on an Agilent Eclipse
XDB-C18 column (250 × 10 mm, 5 μm) with isocratic elution in 80% CH3CN/20% H2O
(0.1% Formic acid) unless otherwise specified.
General Procedure A: Indole N-alkylation
To a suspension of KOH (5 equiv) in DMF (13 mL) was added 5-methoxyindole, 7-
methoxyindole or 7-ethylindole (1 equiv). After stirring at 21 °C for an hour, 1-bromobutane
(1.375 equiv) was added and the reaction mixture was heated to 50 °C and stirred overnight.
Upon completion, the resulting mixture was poured into H2O (15 mL) and extracted with
DCM (3 × 15 mL). Combined organic extracts were washed with water, dried over
anhydrous Na2SO4, concentrated under reduced pressure and the resulting residue was
purified by flash column chromatography on silica gel using EtOAc/n-hexanes.
1-Butyl-7-methoxy-1H-indole (6ac)—Compound 6ac was synthesized from
commercially available 7-methoxyindole using general procedure A and 1-bromobutane to
afford 0.51 g (74% yield) as a clear oil. TLC system: 10% EtOAc/90% n-hexanes. Spectral
data matched previously reported data.41
1-Butyl-7-ethyl-1H-indole (6bc)—Compound 6bc was synthesized from commercially
available 7-ethylindole using general procedure A and 1-bromobutane to afford 0.64 g (93%
yield) as a clear oil. TLC system: 10% EtOAc/90% n-hexanes. 1H NMR (500 MHz, CDCl3)
δ 7.47 (dd, J = 7.6, 1.4 Hz, 1H), 7.05 – 6.95 (m, 3H), 6.47 (d, J = 3.1 Hz, 1H), 4.31 – 4.21
(m, 2H), 3.03 (q, J = 7.5 Hz, 2H), 1.83 – 1.69 (m, 2H), 1.35 (td, J = 7.6, 2.7 Hz, 5H), 0.94 (t,
J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 133.57, 130.09, 129.60, 127.30, 122.42,
119.49, 119.00, 101.40, 48.75, 34.47, 25.67, 20.04, 16.08, 13.77. [M+H] calcd for C14H19N,
202.1590; found 202.1596.
4-(2-(7-Methoxy-1H-indol-1-yl)ethyl)morpholine (6ad)—Compound 6ad was
synthesized from commercially available 7-methoxyindole using general procedure A and 4-
(2-bromoethyl)morpholine that was made utilizing conditions reported by Cai J., et al.42 to
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afford 0.51 g (74% yield) as an oil with a slightly orange tint. TLC system: 40% EtOAc/
60% n-hexanes. 1H NMR (500 MHz, CDCl3) δ 7.20 (dd, J = 7.9, 0.9 Hz, 1H), 7.01 – 6.99
(m, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.61 (dd, J = 7.8, 0.9 Hz, 1H), 6.42 (d, J = 3.1 Hz, 1H),
4.53 – 4.46 (m, 2H), 3.93 (s, 3H), 3.74 – 3.68 (m, 4H), 2.78 – 2.71 (m, 2H), 2.53 – 2.47 (m,
4H). 13C NMR (126 MHz, CDCl3) δ 147.33, 130.92, 129.19, 125.48, 119.75, 113.77,
102.14, 101.33, 67.02, 60.15, 55.15, 53.93, 46.65. [M+H] calcd for C15H21N2O2, 261.1598;
found 261.1603.
1-Butyl-5-methoxy-1H-indole (11)—Compound 11 was synthesized from commercially
available 5-methoxyindole using general procedure A and 1-bromobutane to afford 1.28 g
(92% yield) as a clear oil. TLC system: 10% EtOAc/90% n-hexanes. 1H NMR (500 MHz,
CDCl3) δ 7.18 (d, J = 8.9, 1H), 7.02 (dd, J = 2.7, 13.3, 2H), 6.81 (dd, J = 2.4, 8.9, 1H), 6.34
(dd, J = 0.7, 3.0, 1H), 4.02 (t, J = 7.1, 2H), 3.79 (s, 3H), 1.75 (ddd, J = 7.3, 11.2, 14.8, 2H),
1.32 – 1.23 (m, 2H), 0.87 (t, J = 7.4, 3H). 13C NMR (126 MHz, CDCl3) δ 154.09, 131.56,
129.06, 128.55, 111.93, 110.35, 102.71, 100.53, 56.12, 46.54, 32.63, 20.43, 13.95. [M+H]
calcd for C13H18NO, 204.1383; found 204.1386.
Preparation of 1-butyl-3-iodo-7-methoxy-1H-indole (14)—A round bottom flask
containing 7-methoxyindole (0.22 mL, 1.70 mmol, 1 equiv) in DMF at 21 °C was stirred
with KOH (0.10 g, 1.78 mmol, 1.05 equiv) for 15 min and then treated with I2 (0.44g, 1.73
mmol, 1.02 equiv). After 30 min, NaH (60% dispersion in mineral oil; 0.082 g, 2.04 mmol,
1.2 equiv) was added portion-wise. After an additional 15 min, 1-bromobutane (0.2 mL,
1.87 mmol, 1.1 equiv) was added and the reaction mixture was stirred until completion.
Upon completion (TLC monitoring), water was added and allowed to stir for 15 min, upon
which the mixture was extracted with DCM and the layers were separated. Aqueous layer
was washed with DCM (3 × 15 mL) and the combined organic layers were washed with
H2O (2 × 15 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure.
The resulting residue was purified by silica gel column chromatography using EtOAc/n-
hexanes to afford 0.45g (80% yield) as an clear oil with a yellow tint that was used
immediately. TLC system: 10% EtOAc/90% n-hexanes. 1H NMR (500 MHz, CDCl3) δ 7.08
(t, J = 3.8, 2H), 7.04 (dd, J = 1.1, 8.0, 1H), 6.68 (d, J = 7.5, 1H), 4.38 (t, J = 7.2, 2H), 3.95
(s, 3H), 1.78 (dt, J = 7.5, 12.7, 2H), 1.33 (td, J = 7.5, 15.0, 2H), 0.94 (t, J = 7.4, 3H). 13C
NMR (126 MHz, CDCl3) δ 146.67, 132.31, 131.99, 125.18, 119.88, 113.27, 102.43, 54.80,
48.90, 33.67, 19.20, 13.13.
General Procedure B: O-Demethylation procedure
A solution of BBr3 (1 M in DCM, 6 equiv) in DCM was added dropwise to a solution of
methyl ether (1 equiv) in DCM at −78 °C. The mixture was then allowed to warm to 21 °C
overnight, and upon completion, NaHCO3 (6 equiv) was added. The resulting mixture was
then cooled in an ice-bath and MeOH (20 mL) was added dropwise and then stirred for 30
min. The reaction mixture was then warmed up to 21 °C and stirred for an additional hour.
Upon that, the reaction was quenched with H2O and the separated aqueous phase was
extracted with DCM (3 × 15 mL). Combined organic extracts were dried over anhydrous
Na2SO4, and concentrated under reduced pressure. The resulting residue was purified by
flash chromatography on silica gel using mixtures of EtOAc/n-hexanes.
General Procedure C: Acid chloride formation
The appropriate acid (1 equiv) was placed in a round bottom flask and flushed twice with
Argon (Ar). Anhydrous DCM (7 mL) was then added followed by the dropwise addition of
oxalyl chloride (2 M in DCM, 3.1 equiv). After 5 min, 3 drops of anhydrous DMF were
added to the reaction mixture and once the fizzing stopped, the reaction was allowed to stir
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overnight at 21 °C. Solvent was then evaporated using reduced pressure and the crude
residue was used immediately without any further purification.
General Procedure D: 3′-indole acylation
To a solution of the appropriate indole (1 equiv) in DCM at 0 °C under an Ar atmosphere
was added Me2AlCl (1.5 equiv) dropwise and the solution was allowed to stir at that
temperature for 30 min, after which a solution of the appropriate acid chloride (1.2 equiv) in
DCM was added dropwise. Reaction was monitored by TLC and upon completion, was
carefully poured into an ice-cold 1N HCl solution and then extracted with DCM (3 × 15
mL). Combined organic layers were then washed with NaHCO3 (2 × 15 mL), brine, and
dried over anhydrous Na2SO4. The solvent was evaporated under reduced pressure and the
resulting residue was purified by flash column chromatography on silica gel using mixtures
of EtOAc/n-hexanes to afford the desired product.
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(4-fluorophenyl)ethanone (17)—
Compound 17 was synthesized from compound 6 using general procedure D and 4-
fluorophenylacetyl chloride to afford 0.08g (9% yield) isolated as an brown oil. 1H NMR
(500 MHz, CDCl3) δ 7.98 (dd, J = 0.8, 8.1, 1H), 7.64 (s, 1H), 7.29 – 7.25 (m, 2H), 7.16 (t, J
= 8.0, 1H), 7.02 – 6.96 (m, 2H), 6.71 (d, J = 7.5, 1H), 4.39 (t, J = 7.2, 2H), 4.09 (s, 2H), 3.93
(s, 3H), 1.85 – 1.77 (m, 2H), 1.36 – 1.27 (m, 2H), 0.94 (t, J = 7.4, 3H). 13C NMR (126 MHz,
CDCl3) δ 192.32, 162.72, 160.77, 147.31, 135.78, 131.58, 131.55, 130.88, 130.82, 129.07,
126.33, 123.30, 115.76, 115.38, 115.21, 115.12, 104.31, 55.36, 50.28, 45.87, 33.81, 19.78,
13.68. HRMS (m/z): [M+K] calcd for C21H22FKNO2, 378.1272; found 378.1315. HPLC tR
= 15.031 min; purity = 95.4% using 70% CH3CN/30% H2O (0.1% Formic acid).
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(4-methoxyphenyl)ethanone (18)—
Compound 18 was synthesized from compound 6 using general procedure D and 4-
methoxyphenylacetyl chloride to afford 0.63 g (59.2% yield) isolated as a reddish solid, mp
= 72–74 °C. 1H NMR (500 MHz, CDCl3) δ 8.00 (dd, J = 0.8, 8.1, 1H), 7.63 (s, 1H), 7.25 –
7.21 (m, 2H), 7.15 (t, J = 8.0, 1H), 6.87 – 6.81 (m, 2H), 6.70 (d, J = 7.8, 1H), 4.37 (t, J =
7.2, 2H), 4.06 (s, 2H), 3.92 (s, 3H), 3.77 (s, 3H), 1.84 – 1.76 (m, 2H), 1.35 – 1.26 (m, 2H),
0.93 (t, J = 7.4, 3H). 13C NMR (126 MHz, CDCl3) δ 193.44, 158.73, 147.69, 136.29,
130.73, 129.59, 128.50, 126.69, 123.58, 116.22, 115.62, 114.40, 104.62, 55.76, 55.69,
50.63, 46.48, 34.22, 20.19, 14.11. HRMS (m/z): [M+Na] calcd for C22H25NNaO3,
374.1732; found 374.1783. HPLC tR = 7.490 min; purity = 99.9%.
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(2,3-difluorophenyl)ethanone (19)—
Compound 19 was synthesized from compound 6 using general procedure D and 1-
naphthoyl chloride to afford 2.00 g (53% yield) isolated as pale brown solid, mp = 108–110
°C. 1H NMR (500 MHz, CDCl3) δ 8.19 (d, J = 8.4, 1H), 8.11 (d, J = 7.4, 1H), 7.96 (d, J =
8.2, 1H), 7.91 (d, J = 7.8, 1H), 7.65 (dd, J = 1.1, 7.0, 1H), 7.56 – 7.45 (m, 3H), 7.28 – 7.24
(m, 2H), 7.22 (s, 1H), 6.79 (d, J = 7.7, 1H), 4.30 (t, J = 7.3, 2H), 3.96 (s, 3H), 1.80 – 1.71
(m, 2H), 1.32 – 1.23 (m, 2H), 0.89 (t, J = 7.4, 3H). 13C NMR (126 MHz, CDCl3) δ 192.08,
147.45, 139.32, 139.07, 133.81, 130.89, 129.96, 129.46, 128.22, 126.79, 126.61, 126.34,
126.14, 125.89, 124.65, 123.60, 117.42, 115.35, 104.66, 55.50, 50.34, 33.86, 19.83, 13.73.
HRMS (m/z): [M+Na+CH3CN] calcd for C26H26N2NaO2 421.1892; found 421.1843. HPLC
tR = 14.576; purity = 95.8%.
1-(1-Butyl-7-hydroxy-1H-indol-3-yl)-2-(4-fluorophenyl)ethanone (20)—
Compound 20 was synthesized from 7 using general procedure B to afford 0.10g (38%
yield) isolated as an off-brown solid, mp = decomposition at 204–206 °C. 1H NMR (500
MHz, DMSO) δ 9.91 (s, 1H), 8.44 (s, 1H), 7.62 (dd, J = 0.9, 8.0, 1H), 7.39 – 7.33 (m, 2H),
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7.12 (ddd, J = 2.6, 5.9, 8.9, 2H), 6.94 (t, J = 7.8, 1H), 6.61 (dd, J = 0.9, 7.7, 1H), 4.44 (t, J =
7.0, 2H), 4.09 (s, 2H), 1.85 – 1.75 (m, 2H), 1.31 – 1.21 (m, 2H), 0.90 (t, J = 7.4, 3H). 13C
NMR (126 MHz, DMSO) δ 191.61, 161.72, 159.80, 144.49, 137.94, 132.50, 132.48, 131.05,
130.99, 128.73, 125.46, 122.80, 114.76, 114.59, 114.50, 112.34, 108.26, 48.70, 44.52,
33.29, 18.97, 13.39. HRMS (m/z): [M+Na+CH3CN] calcd for C22H23FN2NaO2, 389.1641;
found 389.1711. HPLC tR = 6.491 min; purity = 99.9% using 70% CH3CN/30% H2O (0.1%
Formic acid).
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-phenylethanone (21)—Compound 21 was
synthesized from compound 6 using general procedure D and phenyacetyl chloride to afford
0.13 g (17% yield) isolated as an off-white solid with a pinkish tint, mp = 65–68 °C. 1H
NMR (500 MHz, CDCl3) δ 8.03 (dd, J = 0.8, 8.1, 1H), 7.66 (s, 1H), 7.36 – 7.30 (m, 4H),
7.26 – 7.22 (m, 1H), 7.18 (t, J = 8.0, 1H), 6.72 (d, J = 7.8, 1H), 4.39 (t, J = 7.2, 2H), 4.14 (s,
2H), 3.94 (s, 3H), 1.87 – 1.77 (m, 2H), 1.32 (dq, J = 7.4, 14.8, 2H), 0.95 (t, J = 7.4, 3H). 13C
NMR (126 MHz, CDCl3) δ 192.72, 147.37, 136.13, 136.06, 129.43, 129.25, 128.62, 126.64,
126.38, 123.30, 115.96, 115.30, 104.34, 55.44, 50.32, 47.09, 33.88, 19.86, 13.78. HRMS (m/
z): [M+Na] calcd for C21H23NNaO2, 344.1626; found 344.1656. HPLC tR = 8.114 min;
purity = 99.9%.
1-(1-Butyl-7-hydroxy-1H-indol-3-yl)-2-phenylethanone (22)—Compound 22 was
synthesized from compound 7 using general procedure B to afford 0.17 g (68% yield)
isolated as a fluffy brown solid, mp = decomposition at 197–200 °C. 1H NMR (500 MHz,
DMSO) δ 9.91 (s, 1H), 8.44 (s, 1H), 7.62 (dd, J = 0.9, 8.0, 1H), 7.36 – 7.31 (m, 2H), 7.28
(dd, J = 4.9, 10.3, 2H), 7.20 (dd, J = 4.3, 11.6, 1H), 6.93 (t, J = 7.8, 1H), 6.61 (dd, J = 0.9,
7.7, 1H), 4.44 (t, J = 7.0, 2H), 4.08 (s, 2H), 1.84 – 1.75 (m, 2H), 1.30 – 1.20 (m, 2H), 0.90 (t,
J = 7.4, 3H). 13C NMR (126 MHz, DMSO) δ 191.75, 144.49, 137.99, 136.39, 129.20,
128.76, 128.00, 126.01, 125.46, 122.77, 114.60, 112.35, 108.24, 48.67, 45.62, 33.28, 18.95,
13.38. HRMS (m/z): [M+Na] calcd for C20H21NNaO2, 330.1470; found 330.1514. HPLC tR
= 6.458 min; purity = 99.8% using 70% CH3CN/30% H2O (0.1% Formic acid).
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(naphthalen-1-yl)ethanone (23)—
Compound 23 was synthesized from compound 6 using general procedure D and 1-
naphthoylacetyl chloride to afford 0.09 g (12% yield) isolated as an amorphous yellow solid,
mp = 110–113 °C. 1H NMR (500 MHz, CDCl3) δ 8.07 – 8.00 (m, 2H), 7.89 – 7.85 (m, 1H),
7.79 (dd, J = 2.4, 7.0, 1H), 7.72 (s, 1H), 7.51 – 7.46 (m, 2H), 7.46 – 7.43 (m, 2H), 7.18 (t, J
= 8.0, 1H), 6.73 (d, J = 7.6, 1H), 4.61 (s, 2H), 4.38 (t, J = 7.1, 2H), 3.95 (s, 3H), 1.85 – 1.77
(m, 2H), 1.34 – 1.24 (m, 2H), 0.94 (t, J = 7.4, 3H). 13C NMR (126 MHz, CDCl3) δ 192.76,
147.41, 135.82, 133.97, 132.76, 132.55, 129.27, 128.76, 127.93, 127.63, 126.32, 126.30,
125.73, 125.57, 124.28, 123.31, 115.99, 115.33, 104.33, 55.45, 50.32, 44.80, 33.84, 19.84,
13.77. HRMS (m/z): [M+K] calcd for C25H25KNO2, 410.1522; found 410.1527. HPLC tR =
11.439 min; purity = 99.8%
1-(1-Butyl-7-hydroxy-1H-indol-3-yl)-2-(naphthalen-1-yl)ethanone (24)—
Compound 24 was synthesized from compound 7 using general procedure B to afford 0.07 g
(55% yield) isolated as an off brown solid, mp = decomposition at 213–216 °C. TLC
system: 30% EtOAc/70% n-hexanes. 1H NMR (500 MHz, DMSO) δ 9.32 (s, 1H), 8.85 (s,
1H), 8.65 – 8.58 (m, 1H), 8.39 – 8.33 (m, 1H), 8.28 (dt, J = 4.3, 8.6, 2H), 8.00 – 7.88 (m,
4H), 7.42 (t, J = 7.8, 1H), 7.15 (d, J = 7.6, 1H), 5.13 (s, 2H), 5.02 (t, J = 7.1, 2H), 2.41 –
2.33 (m, 2H), 1.81 (dq, J = 7.4, 14.9, 2H), 1.40 (t, J = 7.4, 3H). 13C NMR (126 MHz,
DMSO) δ 191.47, 144.32, 136.79, 133.93, 133.52, 132.76, 129.74, 128.34, 128.04, 127.00,
125.69, 125.40, 125.36, 124.74, 122.71, 115.59, 113.81, 108.35, 49.30, 43.73, 33.85, 19.44,
13.07. HRMS (m/z): [M+Na+CH3CN] calcd for C26H26N2NaO2, 421.1892; found
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421.1924. HPLC tR = 6.458 min; purity = 99.8% using 70% CH3CN/30% H2O (0.1%
Formic acid).
(1-Butyl-5-methoxy-1H-indol-3-yl)(naphthalen-1-yl)methanone (25)—Compound
25 was synthesized from compound 11 using general procedure D and 1-naphthoylacetyl
chloride to afford 0.36 g (16% yield) isolated as an amorphous yellow oil. 1H NMR (500
MHz, CDCl3) δ 8.18 (d, J = 8.5, 1H), 8.01 (d, J = 2.5, 1H), 7.96 (d, J = 8.2, 1H), 7.90 (d, J =
7.6, 1H), 7.64 (dd, J = 1.2, 7.0, 1H), 7.54 – 7.44 (m, 3H), 7.28 (d, J = 2.2, 1H), 7.25 (s, 1H),
6.98 (dd, J = 2.6, 8.9, 1H), 4.02 (t, J = 7.2, 2H), 3.92 (s, 3H), 1.81 – 1.71 (m, 2H), 1.32 –
1.22 (m, 2H), 0.88 (t, J = 7.4, 3H). 13C NMR (126 MHz, CDCl3) δ 192.12, 156.75, 139.25,
138.00, 133.81, 131.99, 130.88, 129.96, 128.24, 127.90, 126.80, 126.37, 126.11, 125.83,
124.65, 117.25, 114.28, 110.95, 103.99, 55.93, 47.23, 31.95, 20.11, 13.65. HRMS (m/z): [M
+Na] calcd for C26H26N2NaO2, 421.1892; found 421.1930. HPLC tR = 16.771 min; purity =
99.9% using 70% CH3CN/30% H2O (0.1% Formic acid).
(1-Butyl-5-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone (26)—Compound
26 was synthesized from compound 12 using general procedure B to afford 0.59 g (90%
yield) isolated as a lightly yellow solid, mp = 209–212 °C. TLC system: 30% EtOAc/70% n-
hexanes. 1H NMR (500 MHz, DMSO) δ 9.20 (s, 1H), 8.07 (d, J = 7.8, 1H), 8.02 (d, J = 7.9,
1H), 7.98 (d, J = 8.5, 1H), 7.74 (d, J = 2.4, 1H), 7.65 – 7.59 (m, 3H), 7.58 – 7.54 (m, 1H),
7.50 (ddd, J = 1.4, 6.8, 8.2, 1H), 7.41 (d, J = 8.8, 1H), 6.80 (dd, J = 2.4, 8.8, 1H), 4.11 (t, J =
7.2, 2H), 1.69 – 1.61 (m, 2H), 1.23 – 1.14 (m, 2H), 0.81 (t, J = 7.4, 3H). 13C NMR (126
MHz, DMSO) δ 190.38, 153.63, 138.93, 138.61, 133.14, 130.83, 129.92, 129.30, 128.09,
127.39, 126.46, 126.06, 125.31, 125.20, 124.82, 115.24, 112.81, 111.40, 106.01, 45.86,
31.33, 19.16, 13.27. HRMS (m/z): [M+Na+CH3CN] calcd for C25H24N2NaO2, 407.1735;
found 407.1777. HPLC tR = 13.460 min; purity = 100.0% using 60% CH3CN/40% H2O
(0.1% Formic acid).
1-Butyl-7-methoxy-3-(naphthalen-1-ylmethyl)-1H-indole (27)—LiAlH4 (4.9 mL,
4.85 mmol, 4 equiv) was dissolved in THF (1M) and a solution of AlCl3 (1.94 g, 14.5 mmol,
12 equiv) in THF (8 mL) was added dropwise at 0 °C. After 30 min, indole 3 (0.433 g, 1.21
mmol, 1 equiv) in THF (9 mL) was added to the reaction mixture and allowed to stir at 21
°C for 48 hrs. Upon completion, reaction mixture was cooled in an ice-bath and carefully
quenched with H2O and acidified with 1 N HCl to pH = 3. The organic phase was then
separated and washed with NaHCO3, brine, and dried over anhydrous Na2SO4. The solvent
was evaporated under reduced pressure and the resulting residue was purified by flash
column chromatography on silica gel using mixtures of EtOAc/n-hexanes to afford 0.07 g
(18% yield) isolated as an pinkish oil. TLC system: 10% EtOAc/90% n-hexanes. 1H NMR
(500 MHz, CDCl3) δ 8.11 (d, J = 8.0, 1H), 7.91 – 7.85 (m, 1H), 7.76 (d, J = 8.0, 1H), 7.46
(tt, J = 3.5, 8.3, 2H), 7.42 – 7.34 (m, 2H), 7.21 (dd, J = 0.8, 8.0, 1H), 7.00 (t, J = 7.8, 1H),
6.65 (d, J = 7.5, 1H), 6.50 (s, 1H), 4.51 (s, 2H), 4.24 (t, J = 7.2, 2H), 3.94 (s, 3H), 1.70 (dt, J
= 7.4, 14.8, 2H), 1.24 (dq, J = 7.4, 14.7, 2H), 0.87 (t, J = 7.4, 3H). 13C NMR (126 MHz,
CDCl3) δ 147.93, 137.47, 134.22, 132.61, 130.65, 128.93, 128.32, 127.11, 126.92, 126.31,
126.09, 126.05, 125.83, 124.87, 119.55, 113.82, 112.31, 102.72, 55.68, 49.26, 34.70, 29.37,
20.24, 14.16. HRMS (m/z): [M+] calcd for C24H25NO, 343.1936; found 343.1887. HPLC tR
= 12.038 min; purity = 99.9% using 90% CH3CN/10% H2O (0.1% Formic acid).
(7-Methoxy-1-(2-morpholinoethyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone
(28)—Compound 28 was synthesized from compound 6 using general procedure D and 1-
naphthoylacetyl chloride to afford 0.16 g (16% yield) isolated as an yellow solid, mp = 149–
152 °C. TLC system: 50% EtOAc/50% n-hexanes. 1H NMR (500 MHz, CDCl3) δ 8.18 –
8.10 (m, 2H), 7.95 (d, J = 8.2, 1H), 7.89 (d, J = 7.5, 1H), 7.63 (dd, J = 1.2, 7.0, 1H), 7.54 –
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7.41 (m, 3H), 7.27 – 7.23 (m, 3H), 6.77 (d, J = 7.4, 1H), 4.40 (t, J = 6.5, 2H), 3.94 (s, 3H),
3.60 – 3.49 (m, 4H), 2.67 (t, J = 6.6, 2H), 2.42 – 2.33 (m, 4H). 13C NMR (126 MHz,
CDCl3) δ 192.18, 147.29, 140.00, 139.28, 133.80, 130.86, 130.00, 129.34, 128.26, 126.86,
126.45, 126.38, 126.06, 125.82, 124.55, 123.67, 117.60, 115.47, 104.70, 66.99, 59.29,
55.48, 53.77, 47.37. HRMS (m/z): [M+H] calcd for C26H27N2O3+, 415.2016; found
415.1985. HPLC tR = 7.049 min; purity = 95.0% using 30% CH3CN/70% H2O (0.1%
Formic acid).
1-(1-Butyl-7-hydroxy-1H-indol-3-yl)-2-(4-hydroxyphenyl)ethanone (29)—
Compound 29 was synthesized from compound 7 using general procedure B to afford 0.05 g
(17% yield) isolated as an off-white solid, mp = decomposition at 197–200 °C. TLC system:
30% EtOAc/70% n-hexanes. 1H NMR (500 MHz, Acetone) δ 8.86 (s, 1H), 8.23 (s, 1H),
8.16 (s, 1H), 7.86 (dd, J = 0.9, 8.0, 1H), 7.21 (d, J = 8.6, 2H), 6.98 (t, J = 7.8, 1H), 6.80 –
6.73 (m, 2H), 6.68 (dd, J = 0.9, 7.6, 1H), 4.54 (t, J = 7.1, 2H), 4.01 (s, 2H), 1.94 – 1.85 (m,
2H), 1.39 – 1.29 (m, 2H), 0.94 (t, J = 7.4, 3H). 13C NMR (126 MHz, Acetone) δ 193.14,
156.81, 145.21, 137.93, 131.20, 130.75, 128.46, 126.87, 123.57, 116.43, 115.91, 115.82,
114.76, 109.25, 50.17, 46.31, 34.79, 20.37, 13.99. HRMS (m/z): [M+Na] calcd for
C22H24N2NaO3, 387.1685; found 387.1658. HPLC tR = 4.998 min; purity = 99.4% using
60% CH3CN/40% H2O (0.1% Formic acid).
1-Butyl-7-methoxy-3-(naphthalen-2-yl)-1H-indole (30)—Pd(OAc)2 (2 mg, 0.01
mmol, 0.01 equiv), SPhos (7.4 mg, 0.02 mmol, 0.02 equiv), K3PO4 (379 mg, 1.79 mmol, 2
equiv), and 2-naphthaleneboronic acid (230 mg, 1.34 mmol, 1.5 equiv) were placed into a
round bottom pressure flask and flushed with Ar. Intermediate 14 (294 mg, 0.89 mmol, 1
equiv) in toluene (1 mL) was then added and the reaction mixture was allowed to stir at 100
°C overnight. Reaction was monitored via TLC and upon completion, it was allowed to cool
to 21 °C and diluted with Et2O (10mL). Mixture was then filtered through a pad of Celite
and concentrated under reduced pressure. The resulting residue was purified by flash column
chromatography on silica gel using mixtures of DCM/pentane, to afford 0.15 g (50% yield)
isolated as an clear amorphous oil, TLC system: 15% DCM/85% n-hexanes. 1H NMR (500
MHz, CDCl3) δ 8.10 (s, 1H), 7.93 – 7.84 (m, 4H), 7.80 (dd, J = 1.8, 8.4, 1H), 7.65 (dt, J =
3.2, 6.3, 1H), 7.47 (dddd, J = 1.3, 6.9, 8.0, 16.2, 2H), 7.29 (s, 1H), 7.12 (t, J = 7.9, 1H), 6.72
(d, J = 7.7, 1H), 4.46 (t, J = 7.2, 2H), 3.99 (s, 3H), 1.92 – 1.83 (m, 2H), 1.45 – 1.36 (m, 2H),
0.98 (t, J = 7.4, 3H). 13C NMR (126 MHz, CDCl3) δ 147.84, 134.10, 133.46, 131.93,
128.72, 128.20, 127.80, 127.75, 127.51, 126.71, 126.56, 126.12, 125.11, 125.07, 120.43,
116.57, 112.74, 102.83, 55.45, 49.49, 34.43, 20.06, 13.91. HRMS (m/z): [M+] calcd for
C23H23NO, 329.1780; found 329.1747. HPLC tR = 12.570 min; purity = 96.7% using 90%
CH3CN/10% H2O (0.1% Formic acid).
(1-Butyl-7-methoxy-1H-indol-3-yl)(4-fluorophenyl)methanone (31)—Compound
31 was synthesized from compound 6 using general procedure D and 4-fluorobenzoyl
chloride to afford 0.28 g (49% yield) isolated as an pinkish solid, mp = 91–94 °C. 1H NMR
(500 MHz, CDCl3) δ 8.02 (dd, J = 0.8, 8.0, 1H), 7.89 – 7.84 (m, 2H), 7.45 (s, 1H), 7.26 (t, J
= 8.0, 1H), 7.22 – 7.17 (m, 2H), 6.80 (d, J = 7.4, 1H), 4.44 (t, J = 7.2, 2H), 4.00 (s, 3H), 1.91
– 1.81 (m, 2H), 1.43 – 1.32 (m, 2H), 0.98 (t, J = 7.4, 3H). 13C NMR (126 MHz, CDCl3) δ
189.45, 165.64, 163.64, 147.43, 137.73, 137.34, 137.32, 131.17, 131.10, 129.80, 126.50,
123.39, 115.45, 115.31, 115.28, 115.13, 104.57, 55.49, 50.37, 33.97, 19.90, 13.79. HRMS
(m/z): [M+Na+CH3CN] calcd for C22H23FN2NaO2, 389.1641; found 389.1608. HPLC tR =
8.765 min; purity = 99.8%.
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(2-fluorophenyl)ethanone (32)—
Compound 32 was synthesized from compound 6 using general procedure D and an acid
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chloride made in situ from 2-(2-fluorophenyl)acetic acid43 to afford 0.30 g (35% yield)
isolated as a darker yellow solid, mp = 86–88 °C. 1H NMR (500 MHz, CDCl3) δ 8.04 (dd, J
= 0.8, 8.1, 1H), 7.78 (s, 1H), 7.41 (td, J = 1.7, 7.6, 1H), 7.29 – 7.23 (m, 1H), 7.21 (t, J = 8.0,
1H), 7.16 – 7.07 (m, 2H), 6.75 (d, J = 7.4, 1H), 4.44 (t, J = 7.2, 2H), 4.20 (s, 2H), 3.97 (s,
3H), 1.91 – 1.82 (m, 2H), 1.42 – 1.32 (m, 2H), 0.99 (t, J = 7.4, 3H). 13C NMR (126 MHz,
CDCl3) δ 190.37, 160.78, 158.83, 146.34, 135.04, 135.03, 130.71, 130.67, 128.14, 127.54,
127.48, 125.39, 123.22, 123.19, 122.30, 122.13, 122.01, 114.61, 114.37, 114.19, 114.17,
103.31, 54.40, 49.30, 38.49, 38.48, 32.82, 18.80, 12.73. [M+Na] calcd for C21H22FNNaO2,
362.1532; found 362.1513. HPLC tR = 8.732 min; purity = 99.6%.
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(3-fluorophenyl)ethanone (33)—
Compound 33 was synthesized from compound 6 using general procedure D and an acid
chloride made in situ from 2-(3-fluorophenyl)acetic acid43 to afford 0.21 g (27% yield)
isolated as an yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.98 (dd, J = 0.8, 8.1, 1H), 7.63 (s,
1H), 7.28 – 7.21 (m, 2H), 7.16 (t, J = 8.0, 1H), 7.08 (d, J = 8.1, 1H), 7.03 (d, J = 9.8, 1H),
6.91 (td, J = 1.8, 8.3, 1H), 6.71 (d, J = 7.5, 1H), 4.38 (t, J = 7.2, 2H), 4.10 (s, 2H), 3.92 (s,
3H), 1.85 – 1.75 (m, 2H), 1.36 – 1.25 (m, 2H), 0.93 (t, J = 7.4, 3H). 13C NMR (126 MHz,
CDCl3) δ 191.85, 163.92, 161.97, 147.41, 138.42, 138.36, 135.97, 130.00, 129.94, 129.16,
126.44, 125.18, 125.16, 123.45, 116.54, 116.37, 115.86, 115.21, 113.69, 113.52, 104.46,
55.46, 50.40, 46.55, 46.54, 33.88, 19.87, 13.77. HRMS (m/z): [M+Na] calcd for
C21H22FNNaO2, 362.1532; found 362.1503. HPLC tR = 13.931 min; purity = 99.9% using
50% CH3CN/50% H2O (0.1% Formic acid).
1-(1-Butyl-7-ethyl-1H-indol-3-yl)-2-(4-fluorophenyl)ethanone (34)—Compound 34
was synthesized from compound 6 using general procedure D and 4-fluorophenylacetyl
chloride to afford 0.34 g (39% yield) isolated as an white powder, mp = 67–70 °C. 1H NMR
(500 MHz, CDCl3) δ 8.34 (dd, J = 1.2, 8.0, 1H), 7.72 (s, 1H), 7.32 – 7.27 (m, 2H), 7.25 –
7.20 (m, 1H), 7.10 (d, J = 6.5, 1H), 7.04 – 6.98 (m, 2H), 4.35 – 4.28 (m, 2H), 4.12 (s, 2H),
3.02 (q, J = 7.5, 2H), 1.87 – 1.78 (m, 2H), 1.42 – 1.32 (m, 5H), 0.98 (t, J = 7.4, 3H). 13C
NMR (126 MHz, CDCl3) δ 192.35, 162.81, 160.87, 136.80, 134.58, 131.73, 131.70, 130.95,
130.88, 128.22, 127.79, 124.78, 123.06, 120.82, 115.82, 115.50, 115.33, 49.80, 46.00,
34.07, 25.52, 20.01, 16.28, 13.75. HRMS (m/z): [M+Na+CH3CN] calcd for
C24H27FN2NaO, 401.2005; found 401.1976. HPLC tR = 9.645 min; purity = 99.9%.
1-Butyl-7-methoxy-3-(naphthalen-1-yl)-1H-indole (35)—Intermediate 14 (512 mg,
1.56 mmol, 1 equiv) and Pd(PPh3)4 (54 mg, 0.05 mmol, 0.03 equiv) were placed into a
round bottom flask and flushed with Ar. Solvent (DME, 6 mL) was then added and allowed
to stir for 10 min upon which the solution was degassed by bubbling with Ar for 15 min.
Sodium carbonate (2M [1.06 g in 5 mL H2O, 1.6 ml], 3.11mmol, 2 equiv) and 1-
naphthaleboronic acid (401 mg, 2.33 mmol, 1.5 equiv) in EtOH (1 mL) were added and the
reaction mixture was refluxed. Reaction was monitored via TLC and upon completion, it
was allowed to cool to 21 °C and EtOAc was added. Mixture was then filtered through a pad
of Celite and concentrated under reduced pressure. The resulting residue was purified by
flash column chromatography on silica gel using mixtures of EtOAc/n-hexanes, to afford
0.17 g (37% yield) isolated as an yellow solid, mp = 74–76 °C. TLC system: 10% DCM/
90% n-hexanes. 1H NMR (500 MHz, CDCl3) δ 8.10 (d, J = 8.2, 1H), 7.92 (d, J = 8.2, 1H),
7.85 (d, J = 8.0, 1H), 7.53 (dddd, J = 1.3, 6.9, 8.1, 23.6, 3H), 7.41 (ddd, J = 1.3, 6.8, 8.2,
1H), 7.19 (s, 1H), 7.09 (dd, J = 0.9, 8.0, 1H), 7.00 (t, J = 7.8, 1H), 6.70 (d, J = 7.3, 1H), 4.50
(t, J = 7.1, 2H), 4.01 (s, 3H), 1.95 – 1.86 (m, 2H), 1.47 – 1.37 (m, 2H), 0.99 (t, J = 7.4,
3H). 13C NMR (126 MHz, CDCl3) δ 147.75, 134.08, 133.36, 132.64, 130.54, 128.76,
128.28, 127.75, 126.92, 126.80, 125.90, 125.70, 125.67, 125.65, 119.90, 114.86, 113.25,
102.56, 55.47, 49.36, 34.47, 20.08, 13.93. HRMS (m/z): [M+] calcd for C23H23NO,
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329.1780; found 329.1747. HPLC tR = 11.727 min; purity = 95.4% using 90% CH3CN/10%
H2O (0.1% Formic acid).
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(3,4-difluorophenyl)ethanone (36)—
Compound 36 was synthesized from compound 6 using general procedure D and an acid
chloride made in situ from 2-(3,4-difluorophenyl)acetic acid43 to afford 0.07 g (8% yield)
isolated as an off-white solid, mp = 88–90 °C. 1H NMR (500 MHz, CDCl3) δ 8.01 (dd, J =
0.8, 8.1, 1H), 7.68 (s, 1H), 7.21 (t, J = 8.0, 1H), 7.19 – 7.14 (m, 1H), 7.14 – 7.09 (m, 1H),
7.06 (d, J = 2.2, 1H), 6.76 (d, J = 7.8, 1H), 4.44 (t, J = 7.2, 2H), 4.11 (s, 2H), 3.97 (s, 3H),
1.92 – 1.79 (m, 2H), 1.37 (dq, J = 7.4, 14.8, 2H), 0.99 (t, J = 7.4, 3H). 13C NMR (126 MHz,
CDCl3) δ 191.44, 150.14 (dd, J = 247.8, 12.8 Hz), 149.30 (dd, J = 246.7, 12.6 Hz), 147.32,
135.70, 132.64 (dd, J = 6.0, 4.0 Hz), 128.98, 126.38, 125.38 (dd, J = 6.1, 3.6 Hz), 123.43,
118.36 (d, J = 17.3 Hz), 117.08 (d, J = 17.1 Hz), 115.66, 115.02, 104.41, 55.37, 50.34, 46.07
– 44.76 (m), 33.81, 19.80, 13.68. HRMS (m/z): [M+Na+CH3CN] calcd for
C23H24F2N2NaO2, 421.1704; found 421.1678. HPLC tR = 8.678 min; purity = 100.0%.
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(2,3-difluorophenyl)ethanone (37)—
Compound 37 was synthesized from compound 6 using general procedure D and an acid
chloride made in situ from 2-(2,3-difluorophenyl)acetic acid43 to afford 0.23 g (24% yield)
isolated as an off-brown solid. 1H NMR (500 MHz, CDCl3) δ 8.02 (dd, J = 0.8, 8.1, 1H),
7.78 (s, 1H), 7.21 (t, J = 8.0, 1H), 7.16 (t, J = 6.7, 1H), 7.13 – 7.03 (m, 2H), 6.76 (d, J = 7.4,
1H), 4.45 (t, J = 7.2, 2H), 4.23 (d, J = 1.3, 2H), 3.98 (s, 3H), 1.92 – 1.83 (m, 2H), 1.43 –
1.33 (m, 2H), 0.99 (t, J = 7.4, 3H). 13C NMR (126 MHz, CDCl3) δ 190.40, 150.68 (dd, J =
222.0, 13.0 Hz), 148.72 (dd, J = 220.5, 13.1 Hz), 147.32, 135.89 (d, J = 1.6 Hz), 129.00,
126.37, 126.29 (t, J = 3.2 Hz), 125.38 (d, J = 12.6 Hz), 123.91 (dd, J = 6.9, 4.6 Hz), 123.37,
115.65 (d, J = 17.1 Hz), 115.44, 115.03, 104.36, 55.36, 50.32, 39.10 (t, J = 1.8 Hz), 33.78,
19.76, 13.67. HRMS (m/z): [M+Na+CH3CN] calcd for C23H24F2N2NaO2, 421.1704; found
421.1687. HPLC tR = 8.827 min; purity = 100.0%.
Membrane preparation.27
Mouse brain homogenates for in vitro assays were prepared as previously described.27
Briefly, whole brains were harvested from B6SJL mice, snap-frozen in liquid nitrogen and
stored at −80 °C. On the day membrane homogenates were to be prepared, brains were
thawed on ice, then pooled in a 40 mL Dounce glass homogenizer and suspended in 5
volumes of ice-cold homogenization buffer (50mM HEPES, pH 7.4, 3 mM MgCl2, and 1
mM EGTA). Brains were then subjected to 10 complete strokes with an A pestle, followed
by centrifugation at 40,000 × g for 10 min at +4 °C. Resulting supernatants were discarded,
and the pellet was resuspended, homogenized and centrifuged similarly twice more, with
supernatants being discarded. For the final resuspension and homogenization with a B
pestle, ice-cold 50 mM HEPES was used in place of homogenization buffer and
homogenates were aliquoted and stored at −80 °C. Protein concentrations of homogenates
were determined using the BCA™ Protein Assay (Thermo Scientific, Rockford, IL).
Competition receptor binding assay.28
Competition receptor binding was performed as previously described.28 Briefly, 50 μg of
mouse brain homogenates were incubated for 90 min to attain equilibrium binding at room
temperature with 0.2 nM [3H]CP-55,940, 5 mM MgCl2, and either increasing cannabinoid
concentrations (0.1 nM to 10 μM), 10 μM WIN-55,212-2 (for non-specific binding) or
vehicle (for total binding), in triplicate, in a volume of 1 mL of buffer containing 50 mM
Tris, 0.05% bovine serum albumin (BSA) and 0.1% ethanol vehicle. Reactions were
terminated by rapid vacuum filtration through Whatman GF/B glass fiber filters, followed
by five washes with ice-cold buffer (50 mM Tris, 0.05% BSA). Filters were immediately
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placed into 7 mL scintillation vials to which 4 mL of ScintiVerse™ BD Cocktail scintillation
fluid (Fisher Scientific, Fair Lawn, NJ) was added. Bound radioactivity was determined after
overnight incubation at room temperature and shaking, by liquid scintillation
spectrophotometry with an efficiency of 44% (TriCarb 2100 TR Liquid Scintilation
Analyzer, Packard Instrument Company, Meriden, CT). Specific binding is expressed as
total binding minus non-specific binding, and is graphed for each data point as a percentage
of specific binding occurring in the absence of any competitor.
Adenylyl cyclase assay.28
Four million Neuro2AWT or CHO-hCB2 cells were plated into a 24-well plate and allowed
to attach overnight. At 80–90% confluency (the following morning), 0.5 mL of warm
incubation media composed of DMEM with 0.9g/L NaCl, 2.5 μCi/mL [3H]Adenine and 0.5
mM IBMX was added to the cells. After a 4-hour incubation period at 37°C in a 5% CO2
incubator, the media was removed and the plate was briefly floated on an ice-water bath
while 0.5 mL of an assay mix was quickly added to the cells in triplicate. The assay mix
consisted of a Krebs Ringer HEPES buffered saline solution containing 0.5 mM IBMX, 10
μM forskolin and either vehicle (0.2% ethanol) or at least 6 concentrations (0.1 nM to 10
μM) of each test compound. The plate was then transferred to a 37°C water bath for a 15
minute incubation and the reaction was terminated by addition of 50 μL of 2.2 N HCl.
Intracellular [3H]cAMP was separated by column chromatography employing acidic
alumina. Four mL of the final eluent was added to 10 mL of ScintiVerse™ BD Cocktail
Scintillation Fluid (Fisher Scientific, Fair Lawn, NJ) and radioactivity was immediately
measured employing liquid scintillation spectrophotometry (Tri Carb 2100 TR Liquid
Scintillation Analyzer, Packard Instrument Company, Meriden, CT). Data are expressed as
the percent of intracellular [3H]cAMP relative to that observed in vehicle samples. In
experiments where agonists and antagonists were co-incubated, antagonists were added 5
minutes prior to addition of agonists. Statistical comparison of mean IC50 and IMAX values
(± SEM) for test compounds was accomplished using one-way ANOVA followed by a
Tukey’s post-test.
Animal care and use
Prior to surgery (see below), male NIH Swiss mice (Harlan Sprague Dawley Inc.,
Indianapolis, IN), weighing approximately 25–30 g, were housed 3 animals per Plexiglass
cage (15.24 × 25.40 × 12.70 cm) in a temperature-controlled room at the University of
Arkansas for Medical Sciences, Little Rock, AR. Room conditions were maintained at an
ambient temperature of 22 ± 2 °C at 45–50% humidity. Lights were set to a 12 h light/dark
cycle. Animals were fed Lab Diet rodent chow (laboratory rodent Diet #5001, PMI Feeds,
Inc., St. Louis, MO) and water ad libitum until immediately before testing. Animals were
acclimated to the laboratory environment 2 days prior to experiments and were tested in
groups of 4–8 mice per condition. All studies were carried out in accordance with the
Declaration of Helsinki and with the Guide for Care and Use of Laboratory animals as
adopted and promulgated by the National Institutes of Health. Experimental protocols were
approved by the Animal care and Use Committee at the University of Arkansas for
Medicinal Sciences.
Core temperature measurements
Following appropriate anesthetization with inhaled isoflurane, the abdominal area of each
mouse was shaved and sanitized with iodine swabs. A rostral-caudal cut approximately 1.5
cm in length was made with skin scissors, providing access to the intraperitoneal cavity. A
cylindrical glass encapsulated radiotelemetry probe (model ER-4000 E-Mitter, Mini Mitter,
Bend, OR) was then inserted, and then incision was closed using absorbable 5-0 chromic gut
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suture material. At least 7 days were imposed between surgery and experimental observation
of drug effects to allow incision to heal and mice to recover normal body weights. Following
surgery, implanted mice were individually housed in Plexiglass mouse cages (15.24 × 25.40
× 12.70 cm) for the duration of all temperature experiments. Implanted transmitters
produced temperature-modulated signals that were transmitted to a receiver (model ER-4000
receiver, Mini Mitter Co., Inc) underneath each mouse cage. Receivers were housed in light-
and sound attenuating cubicles (med Associates model ENV-022MD, St. Albans, VT)
equipped with exhaust fans, which further masked ambient laboratory noise. On
experimental days, mice were weighted, marked, and returned to their individual cages for at
least 1 hr of baseline data collection. Cannabinoid doses were then calculated and drugs
were prepared for injection. Animals were subsequently removed from their cage and
injected with various doses of drug or an equivalent volume of vehicle. Temperature data
were collected at regular 5-min intervals and processed simultaneously by the Vital View
data acquisition system (Mini Mitter Co., Inc.) for at least 8 hrs.
Oral EtOH self-administration (two-bottle EtOH choice).44
The standard two-bottle EtOH choice protocol is a widely used oral self-administration
model of ongoing EtOH drinking that captures aspects of voluntary alcohol consumption in
humans. In our procedure, each home cage contained two 25 mL Pyrex glass bottles, capped
with rubber stoppers fitted with stainless steel tips. One bottle contained water while the
other bottle contained a 10% ethanol solution (diluted with tap water). Volumetric
consumption data were recorded from both drinking bottles every Monday and Thursday at
approximately the same time. After recording consumption data, bottles were emptied,
cleaned, refilled to 25 ml, and switched to eliminate a position preference. All animals were
given unrestricted food access (Purina rodent lab diet) during testing, and all mice had 24 h
access to 10% (v/v) EtOH and water for the duration of the study. Drinking preference was
assessed as the amount of EtOH consumed divided by total fluid consumed × 100. Baseline
drinking was established and considered stable when EtOH drinking varied by <10% for
three consecutive days. After baseline criterion drinking was achieved, mice were injected
(i.p.) with 10 mg/kg of the CB1 antagonist rimonabant for 10 consecutive days. After a two
week drug “washout” period, mice were injected with 10 mg/kg 27 or 10 mg/kg 30. After 10
days of treatment with either 27 or 30 was conducted, mice were injected with the drug
vehicle solution for 10 consecutive days. Solutions were prepared fresh weekly with
8%tween and 92% distilled water.
Conditioned place preference.45
Conditioned place preference (CPP) is one of the most popular models to study the
motivational effects of drugs and non-drug treatments in experimental animals, and has been
widely used to evaluate the appetitive effects of abused drugs in mice.45 Our procedure for
establishing CPP involved 3 distinct phases, using Panlab 3-compartment spatial
discrimination chambers. Briefly, these chambers consist of a box with two equally-sized
conditioning compartments connected by a rectangular corridor. The compartments are
differentiated by visual pattern on the walls (dots vs. stripes), color (distinct shades of grey),
floor texture (smooth grid vs. rough), and shape (square vs. multi-angled), providing the
subjects with multiple contextual dimensions across sensory modalities with which to
differentiate the distinct compartments. During the pre-conditioning preference test, mice
were allowed to explore the chamber for 30 min while their behavior was recorded and
scored. These tests occurred on Friday afternoons, and on the next two days mice were
housed in the colony room and not used experimentally. During this time, mice were
assigned to receive EtOH pairings (see below) on their non-preferred side, and saline in their
preferred compartment. On Monday, the conditioning phase began with all mice receiving a
saline injection, then being placed in their preferred compartment for 30 min. During saline
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conditioning, the hallway was blocked so that mice could not leave the conditioning
compartment. After the saline conditioning trial, mice were removed from the chamber and
placed back in their home cage. Approximately 4 hours later, mice were injected with 2 g/kg
EtOH, and then placed into their non-preferred compartment for 30 min. In this manner,
mice were conditioned with both saline and drug each day, and these conditioning trials
occurred Monday through Thursday. On Friday morning, the post-conditioning preference
test was conducted in a manner identical to the preconditioning preference test. For studies
involving CB antagonists, mice were injected with 10 mg/kg rimonabant, 10 mg/kg 27, or
10mg/kg 30 one hour before each EtOH pairing. To calculate a preference (or aversion)
score, the time spent in the drug-paired side during the pre-conditioning test is subtracted
from the time spent in that compartment during the post-conditioning test.
Statistical analysis
Curve fitting and statistical analyses for in vitro experiments were performed using
GraphPad Prism version 5.0b (GraphPad Software, Inc., San Diego, CA). The Cheng-
Prusoff equation was used to convert the experimental IC50 values obtained from
competition receptor binding experiments to Ki values, a quantitative measure of receptor
binding.29 Non-linear regression for one-site competition was used to determine the IC50 for
competition binding. Data are expressed as mean ± SEM. A one-way ANOVA, followed by
Tukey’s Multiple Comparison post-hoc test, was used to determine statistical significance
(P<0.05) between three or more groups. For core body temperature experiments, the area
under the curve (AUC) was calculated using a trapezoidal rule from 0–10 hr. For
temperature data, statistical significance (P<0.05) was determined using a one-way
ANOVA, followed by Tukey’s HSD post-hoc Test. All in vivo statistical calculations were
performed using SigmaStat 3 (Systat Software, Inc., San Jose, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structures of rimonabant (CB1R antagonist/inverse agonist), 1 (CB2R agonist), and 2
(CB2R antagonist)
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Structures of common K2/Spice components and the metabolite of aminoalkylindole 3 (4)
and the classical cannabinoid Δ9-THC
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Compounds 27 and 30 produce very little inhibition of AC-activity when tested alone at
high concentrations and antagonize AC-inhibition produced by CB1R-agonist (black bar in
panel B represents inhibition of AC-activation of 10−7 M concentration of 3)
***Lead compounds selected for testing in animals
a,bDifferent letters signify statistical differences between groups
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Compounds 27 and 30 produce concentration-dependent inhibition of adenylyl cyclase
activity by activation of CB2 receptors
***Lead compounds selected for testing in animals
aLetter signifies statistical differences between groups
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Compounds 27 and 30 reduce agonist 3 induced hypothermic effects in rodents
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Reduction of EtOH self-administration with daily administration of 10 mg/kg rimonabant or
compounds 27 and 30. Dotted lines represent group means from the 10 “no injection”
control periods
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Blockage of EtOH CPP with rimonabant and compounds 27 and 30
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(a) 1-bromobutane or 4-(2-bromoethyl)morpholine, KOH, DMF, 50°C; (b) Me2AlCl,
RCOCl, DCM, 0°C; (c) BBr3, DCM, −78°C; (d) LiAlH4, AlCl3, THF, 0°C
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(a) 1-bromobutane, KOH, DMF, 50°C; (b) Me2AlCl, RCOCl, DCM, 0°C; (c) BBr3, DCM,
−78°C; (d) 1-bromobutane, I2, KOH, DMF, NaH, 50°C; (e) Pd(PPh3)4, 1-
naphthaleneboronic acid, Na2CO3, DME, EtOH; (f) Pd(OAc)2, SPhos, K3PO4, 2-
naphthaleneboronic acid, toluene
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Table 2
Affinity of selected compounds for mouse CB1 and human CB2 receptors
Compound mCB1R Ki ± SEM, nM hCB2R Ki ± SEM, nM
3 (JWH-073) 12.9 ± 3.4 9.8 ± 0.9
4 (JWH-073-M4) 24.2 ± 17.2 78.3 ± 36.2
17 387 ± 77.0 281 ± 51.0
19 1.7 ± 0.3 0.81 ± 0.4
27 15.4 ± 2.2 10.9 ± 3.1
30 37.3 ± 11.8 26.5 ± 1.5
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